Want to see INBX full AI Analyst Report?
Top Page
Inhibrx Biosciences Inc
(NASDAQ:INBX)
Select Model
Select Model
Rating:46Neutral
Price Target:
$87.00
▼(-29.11% Downside)
Action:Reiterated
Date:09/29/26
INBX scores low primarily due to very weak financial performance (minimal revenue, large recurring losses, heavy cash burn, and negative equity), which dominates the risk profile. Technicals are also soft with negative momentum, only partially mitigated by oversold signals. Positive corporate events (strong Phase 2 data and expanded financing capacity) improve the outlook but are not enough to offset current financial strain and loss-making fundamentals.
Positive Factors
Clinical efficacy
The randomized Phase 2 results provide meaningful evidence that INBRX-106 can improve outcomes beyond existing therapy in a serious cancer setting. Higher response rates, complete responses, and longer interim progression-free survival strengthen the pipeline’s clinical and partnering potential.
Negative Factors
No recurring revenue
The absence of recurring commercial revenue leaves the company dependent on financing, collaborations, licensing proceeds, or future product success to fund operations. This makes near-term financial performance highly uncertain and limits the ability to self-fund research and development.
Read all positive and negative factors
Positive Factors
Negative Factors
Clinical efficacy
The randomized Phase 2 results provide meaningful evidence that INBRX-106 can improve outcomes beyond existing therapy in a serious cancer setting. Higher response rates, complete responses, and longer interim progression-free survival strengthen the pipeline’s clinical and partnering potential.
Read all positive factors
Inhibrx Biosciences Inc (INBX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.30B
Dividend Yield5.23%
Average Volume (3M)239.88K
Price to Earnings (P/E)―
Beta (1Y)1.34
Revenue Growth-100.00%
EPS Growth19.23%
CountryUS
Employees110
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)-8.88
Shares Outstanding14,717,660
10 Day Avg. Volume214,916
30 Day Avg. Volume239,885
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)153.07
Price to Sales (P/S)941.13
P/FCF Ratio-9.42
Enterprise Value/Market Cap1.18
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-910.83
Enterprise Value/Ebitda-12.73
Forecast
1Y Price Target
$266.67Price Target Upside117.30% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-9.41
Revenue Forecast (FY)N/A
Inhibrx Biosciences Inc Business Overview & Revenue Model
Company Description
Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which includes a pipeline of novel biologic therapeutic candidates, developed using proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic ca...
How the Company Makes Money
Inhibrx Biosciences, Inc. is a clinical-stage biotechnology company and does not have a stable, product-based commercial revenue stream typical of mature pharmaceutical companies. The company’s cash inflows generally come from (1) collaboration an...
Inhibrx Biosciences Inc Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
18
Very Negative
Cash Flow
14
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 1.30M | 200.00K | 1.80M | 2.19M | 7.13M |
| Gross Profit | -1.68M | -1.18M | -2.08M | 609.00K | -107.99M | 4.44M |
| EBITDA | -120.45M | -125.37M | 1.70B | -206.69M | -125.82M | -75.36M |
| Net Income | -138.18M | -140.06M | 1.69B | -241.36M | -145.23M | -81.77M |
Balance Sheet | ||||||
| Total Assets | 154.22M | 146.48M | 180.77M | 307.89M | 290.88M | 150.45M |
| Cash, Cash Equivalents and Short-Term Investments | 133.34M | 124.22M | 152.60M | 277.92M | 273.87M | 131.30M |
| Total Debt | 5.34M | 107.01M | 8.05M | 210.14M | 207.10M | 72.14M |
| Total Liabilities | 207.20M | 138.49M | 47.18M | 264.39M | 232.82M | 98.07M |
| Stockholders Equity | -52.98M | 7.99M | 133.58M | 43.50M | 58.06M | 52.38M |
Cash Flow | ||||||
| Free Cash Flow | -131.87M | -129.82M | -197.01M | -197.90M | -115.99M | -81.19M |
| Operating Cash Flow | -131.89M | -129.79M | -194.41M | -193.31M | -115.30M | -80.32M |
| Investing Cash Flow | 20.00K | -28.00K | -2.60M | -4.59M | -686.00K | -809.00K |
| Financing Cash Flow | 78.67M | 101.45M | 71.68M | 201.96M | 258.55M | 83.77M |
Inhibrx Biosciences Inc Technical Analysis
Negative
122.72
Price Trends
103.80
Negative
97.21
Negative
92.06
Negative
Market Momentum
-2.79
Negative
39.70
Neutral
56.79
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For INBX, the sentiment is Negative. The current price of 122.72 is above the 20-day moving average (MA) of 93.73, above the 50-day MA of 103.80, and above the 200-day MA of 92.06, indicating a bearish trend. The MACD of -2.79 indicates Negative momentum. The RSI at 39.70 is Neutral, neither overbought nor oversold. The STOCH value of 56.79 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for INBX.
Inhibrx Biosciences Inc Risk Analysis
Inhibrx Biosciences Inc disclosed 89 risk factors in its most recent earnings report. Inhibrx Biosciences Inc reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Inhibrx Biosciences Inc Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | $3.91B | -22.37 | -17.49% | ― | 101.28% | 2.49% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
55 Neutral | $2.03B | -14.04 | -72.07% | ― | -69.78% | -106.07% | |
54 Neutral | $1.61B | -173.49 | -2.35% | ― | 20.19% | ― | |
52 Neutral | $2.17B | -13.45 | -28.66% | ― | -28.56% | 10.25% | |
48 Neutral | $1.07B | -4.02 | -47.04% | ― | -65.40% | -164.71% | |
46 Neutral | $1.30B | -9.98 | 1893.60% | 5.23% | -100.00% | 19.23% |
* General Sector Average
INBX
Inhibrx Biosciences Inc
88.61
29.76
50.57%
XNCR
Xencor
29.18
14.91
104.48%
ZYME
Zymeworks
28.37
9.90
53.60%
IMTX
Immatics
7.15
-3.43
-32.42%
ABCL
AbCellera Biologics
12.08
6.31
109.36%
IMCR
Immunocore Holdings
31.28
-2.18
-6.52%
Inhibrx Biosciences Inc Corporate Events
Business Operations and StrategyFinancial Disclosures
Inhibrx Biosciences Updates Investor Presentation and Pipeline Outlook
Positive
Sep 28, 2026
On September 28, 2026, Inhibrx Biosciences posted an updated corporate investor presentation outlining its pipeline progress, financial position and strategic milestones, including $219.5 million in cash and cash equivalents and 14.7 million commo...
Business Operations and StrategyProduct-Related Announcements
Inhibrx Biosciences reports strong Phase 2 INBRX-106 data
Positive
Sep 8, 2026
On September 8, 2026, Inhibrx Biosciences reported primary endpoint data from the randomized Phase 2 HexAgon trial of INBRX-106 plus pembrolizumab versus pembrolizumab alone in first-line PD-L1–positive metastatic or unresectable recurrent h...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.